Oncobiologics (NYSE: ONS) and Codexis (NASDAQ:CDXS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.
Insider and Institutional Ownership
63.6% of Codexis shares are held by institutional investors. 9.8% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a summary of recent recommendations and price targets for Oncobiologics and Codexis, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Oncobiologics currently has a consensus target price of $9.00, suggesting a potential upside of 615.99%. Codexis has a consensus target price of $7.81, suggesting a potential upside of 23.03%. Given Oncobiologics’ higher probable upside, equities research analysts clearly believe Oncobiologics is more favorable than Codexis.
Earnings & Valuation
This table compares Oncobiologics and Codexis’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Codexis||$48.84 million||6.28||-$8.55 million||($0.41)||-15.49|
Oncobiologics has higher revenue, but lower earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.
This table compares Oncobiologics and Codexis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Codexis beats Oncobiologics on 8 of the 10 factors compared between the two stocks.
Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company’s other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab (Erbitux).
Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.
What are top analysts saying about Oncobiologics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Oncobiologics Inc and related companies.